Cost-Effectiveness of Rivaroxaban versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation in the Guangdong Healthcare Setting in China

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-E-043-Tuesday
• By: ZHOU, Jing (guangzhou, China)
• Co-author(s): Jing Zhou: Department of Pharmacy, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China
  Biyu Huang: Department of Pharmacy, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China
  Min Yang: Department of Pharmacy, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China
  
• Abstract:

  Backgrounds

  Warfarin has been the mainstay of anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Rivaroxaban, a novel oral anticoagulant which offers some distinct advantages over warfarin has been introduced.

  Aims

  To evaluate the cost-effectiveness of rivaroxaban versus warfarin for stroke prevention
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login